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Abstract Extracellular vesicles (EVs) are a heteroge-
neous group of structures which can be classified into
smaller in size and relatively homogenous exosomes
(EXSMs)—spherical fragments of lipid bilayers from in-
ner cell compartments—and bigger in size ectosomes
(ECSMs)—a direct consequence of cell-membrane bleb-
bing. EVs can be found in body fluids of healthy indi-
viduals. Their number increases in cancer and other path-
ological conditions. EVs can originate from various cell
types, including leukocytes, erythrocytes, thrombocytes,
and neoplastic cells. Platelet microparticles (PMPs) are
the most abundant population of EVs in blood. It is well
documented that PMPs, being a crucial element of EVs
signaling, are involved in tumor growth, metastasis, and
angiogenesis and may participate in the development of
multidrug resistance by tumor cells. The aim of this re-
view is to present the role of PMPs in carcinogenesis.
The biology and functions of PMPs with a particular
emphasis on the most recent scientific reports on EV
properties are also characterized.
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Introduction
Extracellular vesicles (EVs) are released under multiple phys-
iological conditions, e.g., cell maturation and aging, by a va-
riety of cells. Their presence was detected in a number of body
fluids of healthy individuals, including peripheral blood,
urine, saliva, semen, cerebrospinal fluid, synovial fluid, bron-
choalveolar lavage, and bile [1, 2]. The mechanism of EV
formation and their biochemical composition depends on the
type and function of cells from which they originate [3]. EVs
express antigens typical of cells from which they are released
and they serve as carriers of many bioactive molecules, in-
cluding proteins, mRNA, and miRNA. Therefore, they play
an important role in cell-to-cell communication.
In 1967, Peter Wolf first identified small procoagulant
structures deriving from activated platelets in human blood
and initially termed them Bplatelet dust^ [3, 4]. This finding
was a milestone in EV research allowing further studies on
their role and function in various disease conditions.
Platelet microparticles (PMPs) are the most abundant mi-
croparticle population in peripheral blood, accounting for
around 70–90 % of all EVs [5–7]. An increase in the number
of PMPs was observed in neurological diseases [2, 8], throm-
botic disorders, primary immune thrombocytopenia, uremia,
and lymphoma [5]. It has been shown that PMPs are actively
involved in angiogenesis [5, 9, 10]. Currently, much attention
is paid to the potential role of EVs, including PMPs, in cancer
progression [11]. It has been suggested that PMPs are able to
promote growth of a primary tumor, can stimulate angiogen-
esis, and contribute to the formation of distant metastases.
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Nevertheless, the basic mechanisms of these phenomena still
need to be elucidated.
Terminology and classification
EVs are a heterogeneous group of predominantly spherical
structures being released by eukaryotic and prokaryotic cells,
both, in vivo and in vitro [12]. Their production increases
during cell activation, oxidative stress, tissue hypoxia, and in
various disease conditions [11, 13, 14]. Lack of standardiza-
tion of definitions deriving from the broad literature on EVs
results in inconsistency in the EV classification schemes. The
absence of unification is likely a consequence of variability in
EVs’ size (from 30 nm to 1 μm) and their diverse cellular
origin. EVs can be divided according to their size into
ectosomes (ECSMs), also called microparticles (MPs) or
microvesicles (MVs), that vary in size between 0.1 and
1 μM, and exosomes (EXSMs) in size of 30–100 nm. EVs
are more commonly classified using their cellular origin.
Using the latter criterion, the following EV categories are
distinguished: platelet microparticles (PMP), erythrocyte mi-
croparticles (RBC-MPs), endothelial cell microparticles
(EMPs), and tumor cell microparticles (TMPs) [15].
Oncosomes are another type of EVs. These particles are much
bigger (1–10 μm) than the ECSMs, are capable of active
movement, and originate from migrating tumor cells [16–18].
EXSMs are relatively homogenous spherical fragments of
lipid bilayers of the inner cell compartments [19, 20], contain-
ing proteins, mRNA, microRNA, and lipids [12, 21].
Exosomes deriving from reticulocytes were first described as
released extracellularly intraendosomal vesicles by Johnstone
in 1987 [21, 22]. Further studies performed on EXSMs in the
80s demonstrated their role in physiological processes, includ-
ing participation in erythrocyte maturation by eliminating
some of erythrocyte surface membrane receptors [1, 22].
Exosomes can derive from various cell types (e.g., platelets,
lymphocytes, astrocytes, fibroblasts, and neoplastic cells) [1,
23, 24] and can be classified according to their functions [25].
Some exosomes participate in antigen presentation and stim-
ulate immune response, while the ones containing RNA are
involved in intercellular communication [26, 27].
ECSMs, other than exosomes, are more diverse and they
form during cell activation due to plasma membrane blebbing
[12, 16, 21, 28]. All MPs are formed directly from the cell
membrane, similar to apoptotic bodies [29, 30] that also be-
long to EVs. However, they can be distinguished from
ectosomes and exosomes due to their different biogenesis
and structures. Apoptotic bodies are 1–5 μm in diameter and
they form by cell-membrane blebbing when the cell un-
dergoes apoptosis; thus, they may contain the nuclear frag-
ments [15, 31–33].
Some authors postulate that the term Bplatelet-derived
microparticles^ should be reserved only for particles between
0.05 and 1 μm in size [33]. Larger may be confused with
platelets or PMPs’ aggregates [34], while the smaller ones
(between 0.04 and 0.08 μm), may be misclassified as
exosomes originating from platelet granules [33, 34]. PMPs
comprise up to 70–90 % of all MVs present in the circulation.
About 10 % of them are derived from granulocytes and only
5% frommonocytes, red blood cells, or endothelial cells [4–6,
35]. Previous reports have also shown that, both, megakaryo-
cytes and immature platelets are able to form MVs [35, 36].
Mechanisms of EV biogenesis
The mechanism of EV formation and their transport to the
extracellular space vary depending on their type [21, 37, 38]
(Fig. 1.). The mechanism of MV formation from endothelial
cells was described for the first time by Biscoe and Stehbens
in 1966. Their discoveries were followed by observations
made by Wolf [39]. The postulated mechanism was based
on fenestration and permeability of endothelial cells of the
arterioles in the carotid glomus. Over three decades later,
in vitro studies have proven that EVs can be also formed from
venous endothelial cells [40]. The exact, likely cell-type spe-
cific, mechanism of their formation through cell membrane
blebbing has not yet been entirely clarified indicating the need
of further studies. On a more general level, EV formation
involves vertical translocation of phospholipids—
phosphatidylserine (PS) and phosphatidyl-ethanolamine
(PE)—and engages actin filaments (AFs) [7, 41].
EXSM formation
During the formation of EXSMs, cell membrane bulges into
the lumen of a late endosome creating a structure called
multivesicular body (MVB) [21, 37]. Endosomal sorting com-
plex required for transport (ESCRT) participates in sorting of
MVB’s content and EXSMs in the cytosol [21], while the
members of Rab family proteins (i.e., Rab11, Rab27a,
Rab27b, Rab35) are involved in the transport, fusion, and
secretion of EXSMs [21]. Also the transmembrane protein
complex SNARE (soluble N – ethylmaleiamide sensitive fac-
tor attachment protein receptor) has been shown to be respon-
sible for the release of EXSMs into the extracellular space [21,
23, 42]. In fact, the structure and chemical composition of
EXSMs are not the same as of the parental cell membrane.
When EXSMs form, PS is transferred to the outer lipid layer
and exposed at the site of membrane fusion. In the same time,
the distribution of membrane proteins remains unchanged
[21]. EXSMs contain proteins and/or nucleic acids (mRNA,
microRNA) specific for their progenitor cells but never all
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proteins of the parental cell membrane are present on
exosomes [30, 43].
ECSM and PMP formation
ECSMs are formed by cel l -membrane budding.
Physiologically phospholipids of the cell membrane are
arranged asymmetrically: phosphatidylcholine (PC) and
sphingomyelin (SM) are present in its outer layer, while
PS and PE in the inner layer. This arrangement is con-
trolled by a group of enzymes, such as flippase,
aminophospholipid translocase, floppase, and scramblase
[21]. Flippase is responsible for the transfer of PE and PS
from the outer to the inner layer of the cell membrane.
Floppase has been shown to have an opposite effect. Their
activity is regulated by ABCC1 protein, also known as a
multidrug-resistance protein 1 (MRP1) [44]. By contrast,
lipid transport is determined by scramblase. Its deficiency
is a rare congenital bleeding disorder associated with
platelet dysfunction named Scott’s syndrome [45]. The
translocation of PS and PE within the lipid bilayer re-
quires energy from ATP hydrolysis [43].
Calcium ions play an essential role in the process of
MP formation. Increased intracellular calcium which is
secondary to its release from endoplasmic reticulum, in-
activates flippase and activates floppase. This leads to
reorganization of phospholipids in the cell membrane
due to degradation by Ca2+-dependent proteolysis [2,
43]. An activation of scramblase requires greater increase
in the calcium concentration and is therefore considered
as less important for the formation of MPs [46]. During
ECSM formation the activation of calpain and gelsolin
occurs. The ability of the latter one to bind and partially
degrade actin filaments leads to breaking of bonds be-
tween the cytoskeleton filaments and phospholipids. The
weakening of the protein fibrils of the cytoskeleton initi-
ates ECSM budding [43, 47].
Platelet activators, such as thrombin, collagen ADP, and
Ca2+ ionophore, activate resting platelets to shed PMPs [3,
4, 48]. The effect of calcium ions and calpain on the formation
of PMPs was demonstrated using platelet activators and their
inhibitors, including thrombin, collagen, and dibucaine [3,
49–51]. Weidmer et al. have shown that preincorporation of
a calpain inhibitor called leupeptin into platelets totally
blocked C5b-9-induced proteolysis of talin, myosin, and actin
binding protein (ABP), having no effect on platelet secretory
activity and formation of PMPs. These data show that forma-
tion of PMPs in response to C5b-9 is dependent upon an
inflow of calcium into the platelet cytosol which does not
require metabolic energy or calpain-mediated proteolysis of
cytoskeletal proteins [52]. Protein tyrosine dephosphorylation
[53] and calmodulin activation [54] are also involved in the
formation of PMPs; however, their role is less clear [3].
PMPs found in peripheral blood express CD41 [5] and
have a short half-life [3, 5]. They are constantly shed into
the circulation in certain amounts even in healthy patients [3,
55]. It is believed that some fraction of circulating PMPs,
named megakaryocyte-derived microparticles (MKMPs),
originates from megakaryocytes [5]. In vitro megakaryocytes
form MKMPs at a diameter of 0.1–0.3 μm [3]. PMPs are also
Fig. 1 Formation of exosomes
(EXSMs) and ectosomes
(ECSMs)
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released during the storage of platelet concentrates. This pro-
cess can be inhibited by administration of platelet activation
inhibitors which does not affect the platelet count [3, 56].
EV structure and components
A hallmark of all EVs is the expression of surface proteins
specific for or associated with their parental cells [57]. The
basic set of proteins located on EXSMs consists of tetraspanin
family proteins (CD9, CD63, CD81, and CD82), lipid-
binding surface protein—milk fat globule EGF/factor VIII
(MFGE8), MHC class I and II molecules, proapoptotic-
apoptosis-linked genes 2 (ALG-2), thioredoxin peroxidase 2
(TPxII) and anti-apoptotic (galantine 3) proteins [58, 59], sur-
face peptidases (CD13, CD26), and protein from tumor sus-
ceptibility gene 101 (TSG101) involved in the MVB biogen-
esis [27, 59]. EXSMs also contain many other proteins, such
as annexins, clathrins, heat shock proteins (HSP), and cyto-
skeletal proteins (actin, myosin). Enzymes present in EXSMs
include enolases, phosphoglycerate kinase, aldolases, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Moreover, they contain translation initiation factor—
eIF4E—and elongation factor—eEF1 [28]. EXSMs’ protein
composition and function prove that rather than being only
spherical fragments of the cell membrane they should be con-
sidered as subcellular compartments formed in a specific and
planned fashion [27].
MPs are less homogeneous structures. Like EXSMs, they
contain numerous markers that determine their origin, e.g.,
CD41 for platelets, CD235a for erythrocytes, and CD11c for
dendritic cells [43, 60]. Their membranes are built out of
phospholipids which have similar composition to those of
the parental cells, particularly their lipid rafts. However, their
membrane profile has not been determined as accurately as the
one of EXSMs [30]. On the other hand, MVs secreted from B
cells, dendritic cells, and melanoma cell lines are richer in
sphingomyelin, rather than in cholesterol which is character-
istic for their parental cells [61].
MPs as EXSMs also contain RNAwhich can mediate ge-
netic communication between cells, for instance, pancreatic
cancer cell lines release PMPs containing mRNAs and
microRNAs [21, 62]. Valadi and colleagues have shown that
exosomes derived from human and mice mast cell lines con-
tain both mRNA and miRNA. The mRNA carried by
exosomes was functional, which means it is capable of
encoding polypeptides in support of protein synthesis.
Interestingly, some miRNAs that they have found in
exosomes were expressed at higher levels than in the donor
cells. Moreover, they have demonstrated that following the
incubation of human cells together with mouse exosomes,
some mouse proteins were found in the recipient cells. The
presence of RNA in exosomes suggests that they act like
vehicles for the gene-based communication between cells;
thus, they may modulate recipient-cell protein production
[62].
PMP structure and components
PMPs contain more than 40 glycoproteins characteristic of
platelets [4, 63–65], including surface markers GP IIa/IIIa
(CD41) and GP Ia/IIa (CD49b/CD29), P-selectin, (CD62),
gp53 (CD63), and receptor present on activated platelets (re-
ceptor of activated glycoprotein IIb/IIIa PAC-1) [4, 66–70].
During activation, platelets release many bioactive sub-
stances, normally stored in their dense and α granules.
Holme et al. have shown that PMPs formed after platelet ac-
tivation by calcium ionophore A23187 contain many proteins
characteristic for α granules of activated platelets, such as
thrombospondin, platelet factor 4, and β-thromboglobulin
[4, 71]. Platelet activating factor (PAF), normally released
from activated platelets under the influence of collagen or
thrombin, was found to be related to PMPs in 90 % [4, 72].
In mice with hemophilia A, PMPs increased after P-selectin
infusion [73], whereas in patients treated with recombinant
activated factor VII (rFVIIa) a temporary increase in the re-
lease of PMPs occurred [74]. PMPs are also able to bind
fibrinogen and participate in thrombus formation [75].
PMPs’ density depends largely on the qualitative and quan-
titative composition of glycoproteins [76, 77]. The majority of
glycoproteins located in the cell membrane consist of adhe-
sion receptors, membrane transporters, andmetalloproteinases
(MMPs). MMPs represent a large group of proteolytic en-
zymes that are able to degrade the components of extracellular
matrix, thus, promoting cancer progression, facilitating tumor
growth, angiogenesis, and metastasis [76, 78–80]. The in-
creased activity of MMPs has been demonstrated in many
tumor types, for instance, membrane-type matrix metallopro-
teinases (MT-MMPs) were shown to be overexpressed in lung
cancer [79, 81–83].
PMPs’ function is multidirectional and their effect depends
on target cell type. [15]. They induce monocyte chemotaxis,
cause an increase in tissue factor (TF) expression on the sur-
face of endothelial cells, and influence adhesion and prolifer-
ation of normal and neoplastic hematopoietic cells. They have
been also shown to be involved in HIV infection [69, 70,
84–87].
PMP elimination
Platelets circulate in human blood for about 10 days. PMPs
injected into mice peripheral blood are cleared from circula-
tion within 20–60 min (unpublished observation of
Flaumenhaft) [3, 15]. Their elimination from the circulation
occurs in several manners. PMPs can be removed by
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phagocytosis after their previous opsonization with comple-
ment proteins, Gas6, thrombospondin, and S protein.
Flaumenhaft has shown that microparticles are opsonized by
C3b complement component [3, 63, 82, 88]. Alternatively,
when opsonization is facilitated by PS externalization, the
process can also occur with the involvement of the C3 com-
ponent [3, 89–91]. When PMPs are released, they remain in
the circulation for only a certain period of time because they
fuse with target cells and because they may be phagocytized
by macrophages, as PMPs express PS on their surface. It has
been shown that following PS binding with annexin V, the
fusion of PMPs with target cell is blocked that prevents ex-
change of their cargo [15]. PMPs may also be eliminated by
serum phospholipase A2 activity [3, 92]. It is still unclear
which of the abovementioned mechanisms is the most signif-
icant mean of PMP elimination. Recently, new PS receptors
have been described, including Tim1 (T cell immunoglobulin
mucin 1), stablin 2, and BAI1 (brain-specific angiogenesis
inhibitor 1), and some of them may be involved in the cellular
uptake of MVs with PS expression [15].
Biological functions of EVs
Many authors emphasize the role of EVs as transcellular sig-
nal delivery particles [66, 67, 93, 94]. It can be hypothesized
that this way of cellular communication is a consequence of
eukaryote evolution and could have preceded the soluble
mediator-based mechanism [69]. Small size of EVs facilitates
long distance movement within body fluids.
The composition of EVs reflecting their cellular origin al-
lows them to transmit specific signals. They can bind to var-
ious target cells exhibiting broad spectrum activity [69]. It is
thought that due to the diversity and the amount of transmitted
information, this type of intercellular communication can play
a crucial role in the modulation of the surrounding microen-
vironment [30, 42]. EVs are able to stimulate target cells di-
rectly by providing ligands which increase the secretion of
various signaling molecules, e.g., growth factors or cytokines
[70, 95, 96]. They can also transfer membrane receptors and
adhesion molecules [97]. Furthermore, EVs deliver proteins,
mRNA, and transcription factors causing epigenetic
reprogramming of target cell [98]. A cell which has internal-
ized EVs can undergo functional transformation and can start
to communicate with the microenvironment in the way it was
programmed by the engulfed particle [11].
Effects of EVs on the immune system
EXSMs first attracted interest of immunologists in 1996 when
it was found that B lymphocytes transformed by Epstein-Barr
virus were able to secrete EXSMs by the fusion ofMVBswith
the plasma membrane. Secreted EXSMs were shown to play a
role in antigen presentation [1, 21]. MVs may act as vectors
for many pathogens and prions [99–101]. MV-associated HIV
transfer is enabled via chemokine receptor CCR5 which is
used by macrophage-tropic HIV-1 to access CCR5+ peripher-
al blood mononuclear cells. This receptor is also expressed on
MVs secreted by peripheral blood mononuclear cells and can
be transferred by MVs to CCR5− cells. This transfer allows
the virus to penetrate target cells [102]. Similar observation
has been made by Rozmyslowicz and colleagues. They have
demons t r a t ed tha t pe r iphe ra l b lood PMPs and
megakaryocyte-derived MPs can transfer the CXCR4 chemo-
kine receptor from the surface of platelets or megakaryocytes
to the surface of CXCR4-null cells that render them more
susceptible for T tropic virus infection (X4 HIV strains, for
which CXCR4 is essential to enter the cell) [94]. In hepatitis C
virus infection, MVs facilitate the transfer of CD81 which is
the crucial co-receptor for B and T cell activation [103].
EXSMs secreted by antigen-presenting cells (APCs) can be
recognized by CD4+ and CD8+ T cells [1]. Studies on
EXSMs deriving from dendritic cells (DCs) showed their abil-
ity to stimulate CD8+ T cells in MHC class I-dependent man-
ner. The stimulation with EXSMs was greater when they de-
rived from mature DCs in comparison with the ones originat-
ing from the more immature cells [104]. EXSMs secreted by
B lymphocytes induce MHC class II-dependent T cell re-
sponse [1].
EXSMs secreted by tumor cells, the so-called tumor extra-
cellular vesicles (TEVs), were found to modulate the immune
response by inhibition of DC differentiation, NK cytotoxic
activity, as well as by promoting the expansion of immuno-
suppressive T regulatory lymphocytes, activated macro-
phages, or NK cells [1, 21]. Their immune-modulatory abili-
ties may find application as a novel therapeutic approach es-
pecially in neoplastic diseases.
PMPs and the immune system
PMPs also have pro-inflammatory effects and may contribute
to the development of certain diseases, such as atherosclerosis
[9]. PMP increase has been observed in patients with acute
coronary syndromes during coronary angioplasty, diabetes
[86, 105], and Alzheimer’s disease [106]. Sprague et al.
showed that PMPs transfer CD154 (CD40L) leading to B-
cell activation [5, 107]. Other studies confirmed modulatory
properties of PMPs at the site of inflammation, including their
ability to induce chemotaxis of monocytes, NK cells, and
lymphocytes [108]. Due to CD41 and CD62P expression,
they may activate neutrophils and endothelial cells emphasiz-
ing their important role in inflammatory processes [109].
PMPs secreted from activated platelets transfer CD41 mem-
brane receptor enhancing the adhesion of hematopoietic cells
to fibrinogen [5, 66]. Furthermore, due to the expression of
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sphingosine 1-phosphate (S1P), they can induce proliferation
of endothelial cells [11, 110]. Also the presence of arachidonic
acid (AA) on their surface allows them to show pro-
angiogenic properties [11, 111–113].
PMPs in cancer development and progression
The role of EVs in cancerogenesis has been demonstrated in
numerous studies and the most attention was brought to
EXSMs, PMPs, and TMVs. Presumably, the abovementioned
particles are involved in tumor growth, metastasis, and angio-
genesis (Fig. 2). Janowska-Wieczorek et al. evaluated the role
of PMPs in the tumor development and metastasis using five
cell lines of human lung cancer and murine Lewis lung carci-
noma cell line (LLC) [67]. Authors have used flow cytometry
to demonstrate that the expression of glycoprotein GPIIb/IIIa
(CD41), specific for platelets and expressed on PMP surface,
was also found on human lung cancer cell lines. It shows that
PMPs can transfer the receptor to the surface of cancer cell
in vitro [67]. Moreover, PMPs were able to stimulate kinase-
dependent protein phosphorylation (MAPK p42 / 44 and
AKT) and increase the expression of matrix metalloprotein-
ases—Type 1 (MT1-MMP) [67]. Authors assessed the ability
of PMP internalization by tumor cells, their impact on cell
activation, and the type of signal pathways involved in this
process [67]. The effect on cell proliferation, expression of
angiogenic factors (including MMPs), and chemoinvasion
was also evaluated [67]. PMPs induced chemotaxis in four
of the cell lines tested. Particles also increased the A549 cell
line proliferation resulting in the formation of distant lung
metastases and abnormal expression of cyclin D2 in C57BL/
6 mice in vivo [67].
PMPs have the ability to induce the expression of
mRNA of MMP-9, vascular endothelial growth factor
(VEGF), and interleukin 8 (IL-8) [67]. The administration
of PMP-coated cells (LLC) to mice resulted in an increase
in the distant metastasis to the bone marrow and lungs
comparing with the control group receiving only the
LLC cells [67, 114]. These observations indicate the par-
ticipation of platelets and PMPs in tumor progression,
metastasis, and angiogenesis [115–117].
A different group of researchers found that PMPs have a
consistent anti-apoptotic effect on human umbilical vein en-
dothelial cells (HUVEC) which depended on the concentra-
tion of thrombin [118]. It has been also shown that this mech-
anism is controlled by the processes crucial for apoptosis in-
duction. Initially, annexin I located on the EMPs participates
in their internalization into endothelial cells through the recep-
tor for phosphatidylserine [118]. Next, inhibition of apoptosis
involves blocking of p38 activation and induces activation of
MAPK phosphatase 1 (MKP-1) and internalization of EMPs
which carries the anti-apoptotic and pro-angiogenic
microRNA (miR-126, miR-296) [119, 120]. Nonetheless, it
is still unclear whether internalization of EMPs occurs via
fusion or phagocytosis [118].
Fig. 2 Platelet microparticles
(PMPs) in tumorogenesis
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Formation of distant metastases requires from the tumor
cells to get through the event cascade that consists of angio-
genesis, passage through the vessel wall, survival in the cir-
culation, and finally proliferation at the site of newly forming
metastases. Bakewell et al. proposed that integrin β3 (hetero-
dimer of αIIbβ5 and αVβ3) plays an essential role in the
formation of metastases [114]. Their further studies confirmed
that mice platelet receptor (GP IIb/IIIa) antagonists play a
protective role in the formation of metastases in bones and
other organs [114] due to their inhibitory properties on the
interaction between the platelets and tumor cells, but also
platelets themselves [114]. Tumor cell-platelet interactions
leading to metastasis are based on the platelet’s ability to ad-
here to the damaged vascular endothelium, as well as their
ability of paracrine regulation of tumor cell proliferation and
growth. Platelets also can protect circulating neoplastic cells
from the cells of immune system. Considering the above,
PMPs’ contribution to metastasis via similar manner, is likely.
EVs may also participate in the development of multidrug
resistance by tumor cells by transferring P-glycoprotein (P-gp)
[121, 122] or by inducing the expression of human epidermal
growth factor receptor 2 (HER2) on their surface. That may
reduce the efficacy of anti-HER2 therapeutic antibody
(Trastuzumab) in breast cancer [121, 123]. MVs can transfer
angiogenic factors intracellularly or pericellulary. They may
induce the expression of pro-angiogenic genes through a di-
rect cellular contact, e.g., with endothelial cells [15, 70, 124,
125]. PMPs’ properties, such as presence of pro-angiogenic
factors from α granules like VEGF, platelet-derived growth
factor, fibroblast growth factor, and metalloproteases, are de-
termined by their platelet origin [15, 35, 70]. Kim et al. eval-
uated PMPs’ contribution to angiogenesis focusing on their
impact on endothelial cell proliferation and survival in vitro
[35]. Other in vivo and ex vivo studies have shown that PMPs
stimulate progenitor cells to form a capillary network [35,
126, 127]. Moreover, MVs secreted by T cells and endothelial
cells modulate angiogenesis, while PMPs stimulate the secre-
tion of pro-angiogenic factors by tumor cells [35, 128]. The
role of TF in tumor growth, angiogenesis, and metastasis is
well documented; therefore, it is not surprising that its pres-
ence on PMPs’ surface was found to facilitate metastasis [35,
129].
Conclusions and future directions
Few preliminary reports suggest only certain benefits of EV-
based therapy. TMPs with high expression of MDR can trans-
fer nucleic acids to MDR (−) tumor cells and can cause drug
resistance. Thus, pharmacologically reduced release of TMPs
represents one of the strategies of anti-cancer therapy. Another
idea is to harness the anti-cancer drug-loaded MVs. It has
recently been shown, in a syngeneic mouse model of CT26
colorectal cancer, that intravenous injection of EVs loaded
with doxorubicin is an effective way to inhibit tumor growth
[130]. Further studies that may reveal other benefits of this
therapeutic approach are warranted.
Numerous studies have been conducted to assess the pos-
sibility of PMP application in the treatment of various dis-
eases. In patients with hormone-refractory prostate cancer
(HRPC), high level of PMPs was correlated with aggressive-
ness of the tumor growth and poor prognosis. While in non-
small cell lung cancer patients, their high levels before and
after the treatment correlated well with prolonged survival [5,
16, 131]. Moreover, in patients with gastric cancer, PMP level
is a better prognostic indicator than IL-6 or VEGF [5, 132].
Although still not used in routine diagnostic PMPs are
regarded as significant prognostic factors in oncological
patients.
Despite the small size of EVs, the ability of their formation
by different cell types, the ease of their travel through the
body, and the magnitude of information they carry make them
a significant factor which regulates the immune response and
modulates the tumor microenvironment. It is well documented
that EVs and PMPs participate in signal transduction into the
cells, including the neoplastic one, thereby modulating their
function. In view of their components, functions, and bioavail-
ability, EVs have been considered as a potentially great vehi-
cle for the administration of drugs and different molecules,
including RNA, to modulate cell activity in many disorders
such as cancer. However, to make EVs applicable and effica-
cious in the treatment, some of their underlying functions still
need to be better understood.
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